Polarean designs and manufactures equipment for production of hyperpolarized xenon or helium gas.
When used in conjunction with MRI, these gases offer a fundamentally new and non-invasive functional imaging platform. Current investigational uses include identifying early diagnoses of respiratory diseases as well as monitoring progression and therapeutic response. In addition, xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.
Polarean hyperpolarization systems are currently sold in the United States and internationally for research and investigational applications only.
Polarean upbeat on results of pilot study
Medical imaging technology company Polarean Imaging announced the allowance of the latest patents on polarisation, the results of a ‘pilot study’ that was undertaken in preparation for its upcoming phase III clinical trials, and an update regarding phase III trials on Friday.
The AIM-traded firm said it has received ‘Notice of Allowance’ on the latest US Patent Application 15/120,013, titled “Hyperpolarized Noble Gas Production Systems with Nanocluster Suppression, Detection, and/or Filtering and Related Methods and Devices”, to which it had exclusive rights.
It said the patent, together with its knowledge, had led to increasing levels of polarisation for its gas-hyperpolarisation platform for MRI.
That was reportedly “key” to advancing image quality, exploring new applications and increasing the overall efficiency of the company’s polarisers.
Polarean also reported completion of the pilot study prior to Phase III clinical trials, reporting that in anticipation of its phase III Trials comparing hyperpolarised 129-Xenon gas MRI to 133Xe scintigraphy – a widely-used imaging technique – it commissioned a pilot study at one of its trial sites.
The pilot study was conducted to validate the study design and the proposed analysis methods of the phase III Trials, along with the proposed analytical methods that would be used in the trials.